Advertisement
Australia markets closed
  • ALL ORDS

    7,817.40
    -81.50 (-1.03%)
     
  • ASX 200

    7,567.30
    -74.80 (-0.98%)
     
  • AUD/USD

    0.6414
    -0.0012 (-0.19%)
     
  • OIL

    82.46
    -0.27 (-0.33%)
     
  • GOLD

    2,397.00
    -1.00 (-0.04%)
     
  • Bitcoin AUD

    100,803.46
    +4,568.07 (+4.75%)
     
  • CMC Crypto 200

    1,334.22
    +21.60 (+1.67%)
     
  • AUD/EUR

    0.6017
    -0.0014 (-0.23%)
     
  • AUD/NZD

    1.0890
    +0.0015 (+0.14%)
     
  • NZX 50

    11,796.21
    -39.83 (-0.34%)
     
  • NASDAQ

    17,394.31
    -99.31 (-0.57%)
     
  • FTSE

    7,831.85
    -45.20 (-0.57%)
     
  • Dow Jones

    37,775.38
    +22.07 (+0.06%)
     
  • DAX

    17,714.38
    -123.02 (-0.69%)
     
  • Hang Seng

    16,224.14
    -161.73 (-0.99%)
     
  • NIKKEI 225

    37,068.35
    -1,011.35 (-2.66%)
     

Analyst Recommendations for Valeant Pharmaceuticals in July

Analyst Recommendations for Valeant Pharmaceuticals in July

In July, the FDA accepted Bausch + Lomb’s NDA (New Drug Application) for sub-micron loteprednol etabonate for the treatment of patients who have undergone ocular surgery and are showing symptoms of post-operative inflammation and pain.